(NUTX) Nutex Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US67079U1088
NUTX: Hospitals, Healthcare, Real Estate, Imaging, Laboratories, Pharmacies
Nutex Health Inc. (NASDAQ:NUTX) is a physician-led healthcare services and operations company that operates through three distinct segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment includes a network of micro-hospitals, specialty hospitals, and hospital outpatient departments, offering 24/7 emergency care, inpatient services, and behavioral health support. Additionally, this segment provides onsite imaging services such as CT scans, X-rays, MRIs, and ultrasounds, as well as certified laboratories and inpatient pharmacies.
The Population Health Management segment focuses on establishing and operating independent physician associations (IPAs) and offers a cloud-based platform designed to enable healthcare organizations to deliver value-based care and manage population health effectively. This platform supports data-driven decision-making, care coordination, and patient engagement, aligning with the shift toward value-based care models in the healthcare industry.
The Real Estate segment involves the ownership and leasing of land and hospital buildings, providing the necessary infrastructure to support the companys healthcare operations. This segment plays a critical role in ensuring that Nutex Healths facilities are well-maintained and strategically located to meet patient needs.
In addition to its core operations, Nutex Health provides a range of operational and managerial services, including management, billing, collections, human resources, legal, accounting, and marketing support. These services are designed to streamline operations for healthcare providers, allowing them to focus on delivering high-quality patient care.
Nutex Health was founded in 2011 and is headquartered in Houston, Texas. The companys integrated approach to healthcare delivery, combining operational efficiency with advanced technology, positions it as a key player in the evolving healthcare landscape. For more information, visit their website at https://www.nutexhealth.com.
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Health Care Equipment
3-Month Forecast:
Based on the provided
Additional Sources for NUTX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NUTX Stock Overview
Market Cap in USD | 281m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2022-04-04 |
NUTX Stock Ratings
Growth 5y | -35.7% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength | 426 |
Analysts | 4.67/5 |
Fair Price Momentum | 77.89 USD |
Fair Price DCF | - |
NUTX Dividends
No Dividends PaidNUTX Growth Ratios
Growth Correlation 3m | 64.3% |
Growth Correlation 12m | 92.9% |
Growth Correlation 5y | -76.7% |
CAGR 5y | -19.48% |
CAGR/Max DD 5y | -0.19 |
Sharpe Ratio 12m | 0.61 |
Alpha | 458.60 |
Beta | 2.222 |
Volatility | 174.99% |
Current Volume | 175.2k |
Average Volume 20d | 42.2k |
As of April 03, 2025, the stock is trading at USD 75.06 with a total of 175,178 shares traded.
Over the past week, the price has changed by +33.25%, over one month by +45.21%, over three months by +116.19% and over the past year by +434.62%.
Probably not. Based on ValueRay Analyses, Nutex Health (NASDAQ:NUTX) is currently (April 2025) not a good stock to buy. It has a ValueRay Growth Rating of -35.69 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NUTX as of April 2025 is 77.89. This means that NUTX is currently overvalued and has a potential downside of 3.77%.
Nutex Health has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy NUTX.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, NUTX Nutex Health will be worth about 84.1 in April 2026. The stock is currently trading at 75.06. This means that the stock has a potential upside of +12.07%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 63.7 | -15.2% |
Analysts Target Price | 55.3 | -26.3% |
ValueRay Target Price | 84.1 | 12.1% |